Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From General Electric
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.
GlaxoSmithKline's market value has slipped in the past three years and the number of failures in the clinic have grown. The major's leadership will be casting nervous glances towards a major shareholder that has a reputation for aggressive restructuring calls.
More C-Suite level pharma executives are lending their domain expertise to private equity firms, which then use their skills for commercial due diligence on targets or in an operating partner role in portfolio companies once a deal is sealed. PEs are also increasingly opting for control deals, at least in India, with an aim to run the acquired firm professionally thereon.
First quarter earnings preview: US drug pricing reform, an uncertain regulatory outlook and new focus on M&A are rising challenges that could put the industry's growth at risk.
- Medical Devices
- Other Names / Subsidiaries
- Clarient Inc.
- Asymptote Limited
- GE Healthcare
- GE Medical Systems LLC
- Monica Healthcare
- Novia Strategies
- Vital Signs.